A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)

Completed · Phase 3

Conditions studied: Advanced Parkinson's Disease

In brief

The primary objective of this study is to examine the effect of LCIG relative to that of OMT on NMS associated with PD.

Key facts

Study ID

NCT02549092

Run by

AbbVie

People needed

89

Starts

2015-10-26

Expected to finish

2022-11-18

Last updated by the study team

2023-11-28

Who can join

Age: 30 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant(s) must have a diagnosis of idiopathic Parkinson's disease according to the United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria.
• Participant(s) demonstrates persistent motor fluctuations in spite of individually optimized treatment.
• The participant's Parkinson's disease is levodopa-responsive.
• Participant(s) has had optimized treatment with available anti-PD medication and their motor symptoms are judged inadequately controlled on this optimized treatment. Optimized treatment is defined as the maximum therapeutic effect obtained with pharmacological antiparkinsonian therapies when no further improvement is expected regardless of any additional manipulations of levodopa and/or other antiparkinsonian medication. This will be based on the Investigator's clinical judgment.
• Male or female participant(s) must be at least 30 years of age.
• Minimum Parkinson's Disease Sleep Scale 2 (PDSS-2) total score of 18 at Baseline assessment.

You may not qualify if…

• Participant's PD diagnosis is unclear or there is a suspicion that the subject has a parkinsonian syndrome such as secondary parkinsonism (e.g. caused by drugs, toxins, infectious agents, vascular disease, trauma, brain neoplasm), parkinson-plus syndrome (e.g. Multiple System Atrophy, Progressive supranuclear Palsy, Diffuse Lewy Body disease) or other neurodegenerative disease that might mimic the symptoms of PD.
• Participant(s) has undergone neurosurgery for the treatment of Parkinson's disease.
• Known hypersensitivity to levodopa, carbidopa or radiopaque material.
• Participant(s) has contraindications to levodopa (e.g. narrow angle glaucoma, malignant melanoma).
• Participant(s) experiencing clinically significant sleep attacks or clinically significant impulsive behavior (e.g. pathological gambling, hypersexuality) at any point during the three months prior to the Screening evaluation as judged by the Principal Investigator.

Where it is running

• Parkinson's and Movement /ID# 161596 — Fountain Valley, California, United States
• Boca Raton Regional Hospital /ID# 200056 — Boca Raton, Florida, United States
• University of Florida Neurolog /ID# 168699 — Jacksonville, Florida, United States
• Parkinson's Disease Treatment Center of Southwest Florida /ID# 168085 — Port Charlotte, Florida, United States
• Rush University Medical Center /ID# 168088 — Chicago, Illinois, United States
• St. Luke's Health System /ID# 168706 — Kansas City, Missouri, United States
• Central Texas Neurology Consul /ID# 168087 — Round Rock, Texas, United States
• Inland Northwest Research /ID# 200113 — Spokane, Washington, United States
• Westmead Hospital /ID# 136575 — Westmead, New South Wales, Australia
• Royal Adelaide Hospital /ID# 136577 — Adelaide, South Australia, Australia
• Royal Melbourne Hospital /ID# 136780 — Parkville, Victoria, Australia
• Goulburn Valley Hospital /ID# 164202 — Shepparton, Victoria, Australia
• University of Alberta /ID# 136586 — Edmonton, Alberta, Canada
• The Ottawa Hospital /ID# 139341 — Ottawa, Ontario, Canada
• Toronto Western Hospital /ID# 136585 — Toronto, Ontario, Canada
• Central Hospital Bremerhaven /ID# 136573 — Bremerhaven, Germany
• 251 Airforce General Hospital /ID# 160594 — Athens, Attica, Greece
• Mediterraneo Hospital /ID# 208042 — Glyfada, Greece
• A.O. Univ. Ospedali Riuniti /ID# 135964 — Ancona, The Marches, Italy
• Ospedale Bellaria.Azienda USL IRCCS.Istituto delle Scienze Neurologiche di Bolog /ID# 136789 — Bologna, Italy
• A.O.U. Ospedali Riuniti di Fog /ID# 136792 — Foggia, Italy
• A.O.U. Policlinico G. Martino /ID# 136790 — Messina, Italy
• Ospedale S.Maria della Miseri /ID# 160609 — Perugia, Italy
• Azienda Sanitaria Locale di /ID# 160608 — Ponderano,biella, Italy
• Azienda Policlinico Umberto I /ID# 201223 — Roma, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.